Screening Instruments for Measuring Visual Symptoms in Victims of Concussion (VISCOM)

January 11, 2024 updated by: Hana Malá Rytter, Bispebjerg Hospital

Visual dysfunction after mild traumatic brain injury (mTBI) is common but often remain undiscovered during longer periods of time. No valid, reliable and easy-to-use screening instrument for uncovering visual dysfunction exists. Furthermore, it is unknown whether optometric measurements currently used in assessing vision problems are consistent with patients' subjective complaints experienced in everyday life. A better understanding of patients' visual challenges combined with objective measurements, will contribute to a better and more efficient diagnostic investigation and treatment.

The aim of this study is to get a better understanding of patients who are suffering from visual dysfunction after mTBI. This understanding will be gained by:

  1. developing and validating a questionnaire for uncovering subjective visual complaints in subjects with mTBI.
  2. developing eye tracking based screening tools applicable both in- and outside of optometry clinics
  3. examining relationships between self-reported data, eye tracking measurements and optometric measurements.

The study will consist of N = 200 subjects. N = 100 of the subjects are suffering from mTBI (commotio group). The second group N = 100 is the non-injured group that preferably will consist of relatives to the subjects in the commotio group. The subjects in both groups have to answer the questionnaires regarding subjective visual complains, undergo optometric tests and undergo eye tracking measurements.

Study Overview

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The subjects (N=200) will be recruited through 5 optometric clinics on Zealand, DK. The objective is to recruit 100 individuals with mTBI and 100 individuals without mTBI (control group). The control group will consist of relatives of the individuals with mTBI, preferably a partner or a sibling.

Description

Inclusion Criteria:

Individuals may be included if they:

  • are adults between the ages 18 and 67
  • have been diagnosed with mTBI by a doctor (emergency room or general practice) either exclusively or with another diagnosis e.g. fracture, neck trauma (doesn't apply to control group)
  • can read and understand Danish
  • continuously have symptoms related to trauma ≥ 2 months and ≤ 24 months after trauma origin (doesn't apply to control group)
  • have best corrected visus at 0.8 or better in both eyes at distance and at near
  • have given informed consent and willingness to participate in the study

Exclusion Criteria:

The following will be excluded if individuals:

  • are diagnosed with one of the following neurological disorders: severe head trauma, brain tumor, Parkinson's disease, multiple sclerosis, dementia
  • are diagnosed with a current active psychiatric disorder
  • are diagnosed with one of the following somatic disorders which are unregulated: diabetes mellitus, metabolic disorders
  • have a verified alcohol or drug abuse
  • have amblyopia (that is, two lines difference or more in best corrected visus between the two eyes)
  • have other visual problems such as constant strabismus, a history of strabismus surgery, congenital nystagmus and recognized eye illnesses such as glaucoma, age- related macular degeneration (AMD)
  • have received vision therapy by an optometrist in relation to resent mTBI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Mild traumatic brain injury group
Consist of patients who have been diagnosed with mTBI by a doctor at an emergency room or in general practice. The patients must still have symptoms related to their trauma ≥ 2 months and ≤ 24 months after trauma origin. They must not have received any vision therapy from an optometrist in relation to resent mTBI.
Non-injured group
The control group will primarily consist of relatives of the individuals with mTBI, preferably a partner or a sibling. The subjects in the control group have to meet the same inclusion and exclusion criteria as the mTBI group, except that they must not be diagnosed with mild traumatic brain injury.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
VISCOM Questionnaire
Time Frame: Estimated duration: 20 minutes
Development and validation of the VISCOM questionnaire consisting of 42 times and establishing a cut-off score, with the aim of uncovering subjective visual symptoms after mTBI. The patients can score their visual symptoms on a Likert scale from 1-5, where one is "never" and five is "always". The higher score the more severe symptoms. The patient symptom score will be compared to the control group symptom score.
Estimated duration: 20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Rivermead Post Concussion Symptoms Questionnaire (RPQ)
Time Frame: Estimated duration in total: 5 minutes
Valid questionnaire consisting 16 items, assessing symptoms after mTBI. The patients can score their visual symptoms from 1-5, one is "not experienced at all" and five is "a severe problem". The higher score, the more server symptoms.
Estimated duration in total: 5 minutes
Vergence facility
Time Frame: Estimated duration in total: 2 minutes
A test of the eyes ability to converge and diverge using a 12 pd base out and 3 pd base in vergence flipper. The result is measured in cycles per minute, using a vertical line of letters 0,4/0,6 ≤ 35 years, and 0,4/1,0 >35 years.
Estimated duration in total: 2 minutes
Fusional vergence at near
Time Frame: Estimated duration in total: 2 minutes
A test of the eyes ability to maintain fusion at 0,4 meter using rotary prism, both positive and negative fusional vergence. The result is measured in prism diopters using a vertical line of letters 0,4/0,6.
Estimated duration in total: 2 minutes
Monocular amplitude of accommodation
Time Frame: Estimated duration in total: 2 minutes
A test of the eyes ability to accommodate using the Accommodation and Near Point Rule. The result is measured in cm using a vertical line with letters 0,4/0,6 with patients ≤ 35 years. The test is done separately with right and left eye.
Estimated duration in total: 2 minutes
Monocular accommodation facility
Time Frame: Estimated duration in total: 2 minutes
A test of the eyes ability to accommodate and relax using a using a ± 2.00 accommodative flipper. The result is measured in cycles per minute, using a vertical line of letters 0,4/0,6 patients ≤ 35 years.
Estimated duration in total: 2 minutes
Horizontal and vertical phoria
Time Frame: Estimated duration in total: 2 minutes
A test of the eyes natural alignment or misalignment using Modified Thorington Test measured in prism diopters at 6 meter and 0,4 meter.
Estimated duration in total: 2 minutes
Near point of convergence
Time Frame: Estimated duration in total: 5 minutes
A test of the eyes ability to converge using the Accommodation and Near Point Rule. The result is measured in cm using a vertical line with letters 0,4/0,6 ≤ 35 years, and 0,4/1,0 >35 years. The test is repeated twice in the optometry clinic and twice using an eye-tracking setup.
Estimated duration in total: 5 minutes
Saccadic eye movement
Time Frame: Estimated duration in total: 10 minutes
A test of the of saccades using 3 test cards and one demonstration card, in the optometry clinic and also using an eye-tracking setup. The result is measured in seconds and errors in total.
Estimated duration in total: 10 minutes
Reaction test
Time Frame: Estimated duration in total: 5 minutes
An eye-tracking test of the participant's reaction time for a visual target appearing after a random delay. The result is measured as delay from the target appears to the following reactions: eye movement initiation, target fixation. Additionally, the accuracy of the initial fixation is measured. The test is repeated 24 times with delays drawn from three normal distributions. The delays are identical between participants.
Estimated duration in total: 5 minutes
Pattern test
Time Frame: Estimated duration in total: 5 minutes
An eye-tracking test of the participant's ability to follow a moving circular target placed in a grid of identical moving targets. The target's position and direction of movement is indicated before the test is started. The result is measured as average fixation accuracy over the test period. The test is repeated 24 times with varying movement speed, direction, and target size.
Estimated duration in total: 5 minutes
Saccade test
Time Frame: Estimated duration in total: 5 minutes
An eye-tracking of the participant's ability to quickly move their eyes between two targets in a given timeframe. The targets are circular and vary in size and position for each test repetition. The result is measured in number of correct saccades between the targets as well as the average fixation error (fixation distance outside target).
Estimated duration in total: 5 minutes
Smooth pursuit test
Time Frame: Estimated duration in total: 5 minutes
An eye-tracking of the participant's ability to follow a small circular target's movements across a screen at various speeds and movement patterns. The test is repeated a total of 25 times comprised of 5 movement speeds for each of 5 patterns (horizontal line, vertical line, two diagonal lines, circle). The result is measured as average target deviation, number and duration of blinks, and number and amplitude of saccadic movements.
Estimated duration in total: 5 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nystagmus test
Time Frame: Estimated duration in total: 5 minutes
An eye-tracking test of the participant's ability to hold each eye still in an outward position for a duration of 10 seconds. The result is measured in the number and amplitude of saccadic movements over the time period.
Estimated duration in total: 5 minutes
Stereopsis
Time Frame: Estimated duration in total: 2 minutes.
A test and evaluation of the eyes depth perception using polaroid glasses and Random Dot Stereotest. The result is measured in seconds of arc.
Estimated duration in total: 2 minutes.
Vectogram no.12
Time Frame: Estimated duration in total: 2 minutes
The Vectogram no. 12 test is done at 0,4 meter, while the patient is reporting how exhausting the test is on a score from 1-5, where one is "easy and without trouble" and 5 is "unbearable exhausting". The result from the Vectogram no. 12 is measured in prism diopters.
Estimated duration in total: 2 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hana M Rytter, PhD, Bispebjerg Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2022

Primary Completion (Estimated)

May 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

March 23, 2023

First Submitted That Met QC Criteria

May 15, 2023

First Posted (Actual)

May 17, 2023

Study Record Updates

Last Update Posted (Actual)

January 12, 2024

Last Update Submitted That Met QC Criteria

January 11, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Concussion

Subscribe